LaChapelle Robin
Reporting owner on Forms 3, 4 and 5, CIK 2009136.
LaChapelle Robin reported on 1 issuer in 1 filing, the latest a Form 4 filed 2026-11-02.
Issuers
| Issuer | Roles in the latest filing | Filings | Last filed |
|---|---|---|---|
| AVBP · ArriVent BioPharma, Inc.CIK 1868279 | officer (Chief Operating Officer) | 1 | 2026-11-02 |
Transactions and holdings
Every row of the person's Forms 3, 4 and 5, newest first, with the price and the amount owned after the row as filed.
| Security | Date | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| AVBP · ArriVent BioPharma, Inc.Common Stock | 2026-10-30 | M exercised | +16,265 | $3.6504 | 152,001 | Form 4 |
| AVBP · ArriVent BioPharma, Inc.Common Stock | 2026-10-30 | M exercised | +410 | $2.2815 | 152,411 | Form 4 |
| AVBP · ArriVent BioPharma, Inc.Common Stock | 2026-10-30 | M exercised | +4,550 | $2.2815 | 156,961 | Form 4 |
| AVBP · ArriVent BioPharma, Inc.Common Stock | 2026-10-30 | M exercised | +1,820 | $2.2815 | 158,781 | Form 4 |
| AVBP · ArriVent BioPharma, Inc.Common Stock | 2026-10-30 | M exercised | +17,648 | $6.2361 | 176,429 | Form 4 |
| AVBP · ArriVent BioPharma, Inc.Common Stock, holding | 394,477 | Form 4 | ||||
| AVBP · ArriVent BioPharma, Inc.Stock Option (right to buy), derivative | 2026-10-30 | M exercised | -410 | $0 | 0 | Form 4 |
| AVBP · ArriVent BioPharma, Inc.Stock Option (right to buy), derivative | 2026-10-30 | M exercised | -4,550 | $0 | 1,820 | Form 4 |
| AVBP · ArriVent BioPharma, Inc.Stock Option (right to buy), derivative | 2026-10-30 | M exercised | -1,820 | $0 | 0 | Form 4 |
| AVBP · ArriVent BioPharma, Inc.Stock Option (right to buy), derivative | 2026-10-30 | M exercised | -16,265 | $0 | 2,600 | Form 4 |
| AVBP · ArriVent BioPharma, Inc.Stock Option (right to buy), derivative | 2026-10-30 | M exercised | -17,648 | $0 | 38,823 | Form 4 |
Filings
The person's Forms 3, 4 and 5, and any 13D or 13G naming it.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| Form 4 0001104659-26-121410 | ArriVent BioPharma, Inc. | 2026-11-02 |